deltatrials
Completed PHASE3 NCT00000555

Women's Angiographic Vitamin and Estrogen Trial (WAVE)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Cardiovascular Diseases Coronary Arteriosclerosis Coronary Disease Heart Diseases Myocardial Ischemia Postmenopause
Interventions ascorbic acid estrogen replacement therapy estrogens, conjugated hormone replacement therapy progesterone supplementation, food vitamin e
Updated 5 times since 2017 Last updated: Jul 11, 2016 Started: Aug 31, 1996 Completion: May 31, 2003

This PHASE3 trial investigates Cardiovascular Diseases and Coronary Arteriosclerosis and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 5 recorded versions since 1996 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.